Top 5 Prostate Cancer Trials of 2024 by Toni Choueiri
Toni Choueiri, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, posted on X:
“And NOW, TOP 5 PROSTATE CANCER trials of 2024!
1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%, – Benefits seen across all subgroups with a favorable safety profile.
A new player for doublets in mHSPC!
2) PSMAfore: Phase 3 trial of Lu-PSMA-617 shows a 46% reduction in progression risk vs ARPI change in taxane-naive mCRPC patients.
Median rPFS: 11.6 vs 5.6 months. Favorable safety profile makes it a promising alternative!
3) UpFrontPSMA: Adding [177Lu]Lu-PSMA-617 before docetaxel significantly improved undetectable PSA rates (41% vs 16%) in high-volume metastatic hormone-sensitive prostate cancer, with no increased toxicity.
A promising step forward!
4) RADICALS-HD trial: No difference in metastasis-free survival (MFS) between 0, 6, or 24 months of ADT with postoperative radiotherapy in prostate cancer. Long-term outcomes are favorable, suggesting ADT may not always be needed.
Focus on high-risk patients!
5) Not a trial, but as important and proud of Mark Pomerantz our clinical director for his AACR paper: Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer:
- Germline BRCA2 variants do not worsen outcomes in high-risk prostate cancer but worse overall survival was observed in de novo metastatic cases (HR 1.59).
- Results for other DNA repair genes were limited due to their rarity.
- Precision insights for tailored care!”
Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023